The transfer of the Cancer Therapy &Research Center (CTRC) and the Cancer Center Support Grant (CCSG) from the CTRC Foundation to the University of Texas Health Science Center at San Antonio (UTHSCSA) in December 2007 was the largest gift in the history of University of Texas (UT) System. A major component of the gift was the entire physical plant of the CTRC, a 330,000 sq. ft. facility dedicated to cancer treatment and research with a focus on clinical research. This physical location is the recognized home of the CTRC and is well recognized by the public as """"""""The Cancer Center."""""""" The CTRC physical plant is composed of three buildings which house the multi-disciplinary outpatient clinics and conventional and research infusions suites, a pharmacy. Radiation Oncology facilities the Clinical Trials Office (CTO), conference rooms, two research laboratories and the Administrative Offices of the CTRC . Since the integration of the CTRC into the UTHSCSA, the UTHSCSA has opened a new research building, the South Texas Research Facility (STRF), located adjacent to the CTRC building. The STRF, a 190,000 sq.ft. building containing both office space and wet laboratories, opened in October 2012. The UTHSCSA allocated 25,000 sq. ft. of the STRF's research laboratories to the CTRC adding to the CTRC's research space. The CTRC Director has authority to assign all CTRC-designated space (as listed in Table 1). Should an investigator leave the CTRC, any vacated CTRC-designated space reverts back to the CTRC. Additional space (-38,0000 sq. ft.) in various departments of the UTHSCSA is used for cancer research but is under the control of the respective Department Chairs in collaboration with the CTRC Director. When new recruits with a cancer focus are identified, space for the investigator's cancer research is negotiated in consultation with the CTRC Director. In many cases, the CTRC provides support for the start-up package and the departments provide the space. In some cases, the opposite is true and the CTRC provides space while the department contributes to the startup package.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758449
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$177,835
Indirect Cost
$13,244
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications